US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (LXRX) ニュース

LXRX

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LXRX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/15	06 : 05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	20 : 00	GlobeNewswire Inc.	New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/11	06 : 14	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/11	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/09	20 : 30	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/03	05 : 05	GlobeNewswire Inc.	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/29	22 : 00	GlobeNewswire Inc.	Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/29	20 : 00	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/18	21 : 00	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Host 2024 Investor Day	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/03	21 : 00	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/25	22 : 20	GlobeNewswire Inc.	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/12	21 : 00	GlobeNewswire Inc.	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/12	05 : 25	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20 : 15	GlobeNewswire Inc.	Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20 : 05	GlobeNewswire Inc.	Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20 : 00	GlobeNewswire Inc.	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/01	06 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/01	06 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:LXRX

1 2 3 4 5 6 7 8 9 10 次へ >>

Newday Fmi 25 A

Fidelity Advisor Municip...

PT Sampoerna Agro TBK (GM)

Vontobel Financial Produ...

OC1N24 - Julho 2024

Bearclaw Capital

Amaya Big Sky Capital

Stanley Furniture (QB)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約